{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-23-000064","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.065514+00:00","generated_at":"2026-06-09T07:45:47.288439+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"West Pharma Q3: adj EPS $2.16, rev $747.4M; raises FY adj EPS outlook to $7.95-8.00","bullets":["Q3 net sales $747.4M, +8.8% YoY; organic growth 5.7%.","Reported diluted EPS $2.14 (+34.6%); adjusted diluted EPS $2.16 (+6.4%).","FY2023 net sales guidance cut to $2.950-2.960B (from $2.970-2.995B); organic growth now 2-3%.","FY2023 adjusted EPS guidance raised to $7.95-8.00 (from $7.65-7.80); dividend increased to $0.20/share (+5.3%).","Proprietary Products net sales +6.3% (organic +3.2%); Contract-Mfg +20.8% (organic +17.4%)."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-23-000064","json":"https://secwatch.observer/filing/0000105770-23-000064.json","markdown":"https://secwatch.observer/filing/0000105770-23-000064.md","text":"https://secwatch.observer/filing/0000105770-23-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000064/0000105770-23-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000064/wst-20231026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T07:45:47.288439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89c33c6ee9b70cb1f8162a0a380866734307ad33","claim":"WEST PHARMACEUTICAL SERVICES INC reported Third-Quarter 2023 results: revenue Net sales of $747.4 million grew 8.8%; organic net sales growth was 5.7%., EPS Reported-diluted EPS of $2.14 increased 34.6%..","evidence_excerpt":"West Announces Third-Quarter 2023 Results, Updates Full-Year 2023 Guidance and Declares Fourth-Quarter 2023 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, October 26, 2023 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2023, updated full-year 2023 financial guidance and declared a fourth-quarter 2023 dividend. Third-Quarter 2023 Summary (comparisons to prior-year period) • Net sales of $747.4 million grew 8.8%; organic net sales growth was 5.7%. • Reported-diluted EPS of $2.14 increased 34.6%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000064/0000105770-23-000064-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Third-Quarter 2023"},{"label":"Revenue","value":"Net sales of $747.4 million grew 8.8%; organic net sales growth was 5.7%."},{"label":"EPS","value":"Reported-diluted EPS of $2.14 increased 34.6%."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}